Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun;43(6):824-831.
doi: 10.1161/ATVBAHA.123.318779. Epub 2023 May 4.

Updates in the Incidence, Pathogenesis, and Management of Cancer and Venous Thromboembolism

Laura Girardi  1 , Tzu-Fei Wang  2 , Walter Ageno  1 , Marc Carrier  2
Affiliations
Free article
Review

Updates in the Incidence, Pathogenesis, and Management of Cancer and Venous Thromboembolism

Laura Girardi et al. Arterioscler Thromb Vasc Biol. 2023 Jun.
Free article

Abstract

Patients with cancer are at higher risk of developing venous thromboembolism (VTE) compared with the general population. This elevated risk is due to several risk factors and multiple, overlapping thrombotic and hemostatic pathophysiological pathways that are specific to this patient population. Hence, the management of cancer-associated VTE can be challenging for clinicians. Patients with cancer-associated VTE are at higher risk of both recurrent events despite anticoagulation and bleeding complications due to the anticoagulant regimens. Direct oral anticoagulants have recently been shown to be effective, safe, and more convenient than parenteral low-molecular-weight heparin for the management of cancer-associated VTE. Despite these recent advances in anticoagulant therapy, many unmet needs remain in these patients (increased risk of bleeding with specific cancer types, drug-drug interactions, liver dysfunction). Factor XI inhibitors are currently being assessed for the management of cancer-associated VTE and may help clinicians address these important knowledge gaps.

Keywords: anticoagulants; hemorrhage; neoplasms; venous thromboembolism; venous thrombosis.

PubMed Disclaimer

Conflict of interest statement

Disclosures T.-F. Wang reports advisory board honoraria from Servier and Valeo and research funding to the institution from Leo Pharma. W. Ageno reports advisory board honoraria from Bayer, Boehringer Inghelheim, Daiichi Sankyo, Bristol-Myers Squibb (BMS)/Pfizer, Sanofi, and Portola and reports research funding and personal fees from Bayer and personal fees from BMS/Pfizer, Daiichi Sankyo, Sanofi, Aspen, Janssen, and Portola, outside the submitted work. M. Carrier has received research funding from BMS, Pfizer, and Leo Pharma and honoraria from Bayer, Pfizer, BMS, Servier, and Leo Pharma. The other author reports no conflicts.

MeSH terms

Substances